RxDoctor Payments Data

Kaushal Patel, MD

Pulmonary Disease · Newport News, VANPI 1396186466

Payments from drug & device makers

$3,196in general payments, 2019–2025

Across 58 payments — averaging $55.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Veran Medical Technologies, Inc.$1K
  • Intuitive Surgical$1K
  • GSK$195
  • AstraZeneca$106
  • Inspire Medical Systems, Inc.$82
  • Sunovion Pharmaceuticals Inc.$66
  • plus $302 from 12 others

What the payments were for

  • Travel & lodging$2,17468%
  • Food & beverage$99531%
  • Education$271%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,196 in reported general payments places this provider in the 50th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$83,488
Medicare patients
426
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter355$298,968
TezspireTezepelumab-Ekko16$73,008
XolairOmalizumab14$53,388
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr81$44,459
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$26,243
Breo ElliptaFluticasone/Vilanterol45$23,334
Advair HfaFluticasone Propion/Salmeterol16$7,425
DuleraMometasone/Formoterol12$6,204
Albuterol Sulfate HfaAlbuterol Sulfate149$4,642
Arnuity ElliptaFluticasone Furoate17$4,031
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$3,433
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,539
Wixela InhubFluticasone Propion/Salmeterol16$1,794
Ventolin HfaAlbuterol Sulfate23$1,351
Azelastine Hcl18$544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$195$370,792498 claims
AstraZenecaTezspire$106$73,00816 claims
Boehringer IngelheimStiolto Respimat$42$26,24331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →